Reported 2 days ago
Regeneron Pharmaceuticals and Sanofi have reported encouraging interim results from their Phase 4 DISCOVER trial of Dupixent (dupilumab) for treating moderate-to-severe atopic dermatitis in adolescents and adults with skin of color. Presented at the 2025 RAD Conference, the trial demonstrated that 76% of participants achieved significant improvement in disease severity after 24 weeks of treatment.
Source: YAHOO